IL118356A0 - Method of administration of IGF-I - Google Patents

Method of administration of IGF-I

Info

Publication number
IL118356A0
IL118356A0 IL11835696A IL11835696A IL118356A0 IL 118356 A0 IL118356 A0 IL 118356A0 IL 11835696 A IL11835696 A IL 11835696A IL 11835696 A IL11835696 A IL 11835696A IL 118356 A0 IL118356 A0 IL 118356A0
Authority
IL
Israel
Prior art keywords
administration
mammal
igf
period
time
Prior art date
Application number
IL11835696A
Other languages
English (en)
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of IL118356A0 publication Critical patent/IL118356A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/30—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/556—Angiotensin converting enzyme inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Obesity (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Neurology (AREA)
  • Urology & Nephrology (AREA)
  • Child & Adolescent Psychology (AREA)
  • AIDS & HIV (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Reproductive Health (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
IL11835696A 1995-05-22 1996-05-22 Method of administration of IGF-I IL118356A0 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/445,805 US5741776A (en) 1995-05-22 1995-05-22 Method of administration of IGF-I

Publications (1)

Publication Number Publication Date
IL118356A0 true IL118356A0 (en) 1996-09-12

Family

ID=23770265

Family Applications (1)

Application Number Title Priority Date Filing Date
IL11835696A IL118356A0 (en) 1995-05-22 1996-05-22 Method of administration of IGF-I

Country Status (16)

Country Link
US (1) US5741776A (ja)
EP (1) EP0827408B1 (ja)
JP (2) JPH11505265A (ja)
AT (1) ATE343395T1 (ja)
AU (1) AU699113B2 (ja)
CA (1) CA2218018A1 (ja)
DE (1) DE69636654T2 (ja)
DK (1) DK0827408T3 (ja)
ES (1) ES2275276T3 (ja)
HK (1) HK1009744A1 (ja)
IL (1) IL118356A0 (ja)
MX (1) MX9708918A (ja)
NZ (1) NZ307913A (ja)
PT (1) PT827408E (ja)
WO (1) WO1996037216A1 (ja)
ZA (1) ZA963995B (ja)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6239172B1 (en) * 1997-04-10 2001-05-29 Nitrosystems, Inc. Formulations for treating disease and methods of using same
US20110196039A9 (en) * 1994-10-05 2011-08-11 Kaesemeyer Wayne H Controlled release arginine formulations
EP0956041A1 (en) * 1996-09-16 1999-11-17 Dalhousie University Use of igf-i for the treatment of polycystic kidney disease and related indications
ATE233097T1 (de) 1997-11-07 2003-03-15 Chiron Corp Verfahren zur herstellung von igf-i formulierungen mit verzögerter freisetzung
AU3548999A (en) 1998-04-03 1999-10-25 Chiron Corporation Use of igfi for treating articular cartilage disorders
WO2000040612A1 (en) * 1999-01-06 2000-07-13 Genentech, Inc. Insulin-like growth factor (igf) i mutant variants
JP3971108B2 (ja) * 1999-01-06 2007-09-05 ジェネンテック・インコーポレーテッド インシュリン様成長因子（ｉｇｆ）ｉ突然変異体
DE60020677T2 (de) 1999-02-26 2006-05-04 Chiron Corp., Emeryville Mikroemulsionen mit adsorbierten makromolekülen und mikropartikeln
US6040292A (en) * 1999-06-04 2000-03-21 Celtrix Pharmaceuticals, Inc. Methods for treating diabetes
US7713739B1 (en) 2000-11-17 2010-05-11 Novartis Vaccines And Diagnostics, Inc. Microparticle-based transfection and activation of dendritic cells
DE19951471A1 (de) * 1999-10-26 2001-05-03 Forssmann Wolf Georg Verwendung von Urodilatin zur Behandlung chronischer Niereninsuffizienz mit Nierenrestfunktionen
EP1282437B1 (en) 2000-05-16 2008-03-19 Genentech, Inc. Treatment of cartilage disorders
WO2005020933A2 (en) 2003-09-02 2005-03-10 University Of South Florida Nanoparticles for drug-delivery
DK2274978T3 (en) * 2003-09-12 2015-06-15 Ipsen Biopharmaceuticals Inc Methods of treating an insulin-like growth factor-I (IGF-I) deficiency
WO2006085631A2 (en) * 2005-02-08 2006-08-17 Japan As Represented By President Of National Cardiovascular Center Novel method for treating chronic severe heart failure by using insulin-like growth factor-1 (igf-1)
PL2510942T3 (pl) 2005-04-07 2016-02-29 Cardiorentis Ag Zastosowanie peptydu natriuretycznego do leczenia niewydolności serca
US8158582B2 (en) * 2005-06-02 2012-04-17 Tercica, Inc. Methods for treatment of insulin-like growth factor-1 deficiency
WO2007014167A2 (en) * 2005-07-22 2007-02-01 Five Prime Therapeutics, Inc. Compositions for and methods of treating epithelial diseases with growth factors
ES2325432B1 (es) * 2006-01-13 2010-06-09 Universidad De Malaga Utilizacion de dosis bajas de igf-i en el envejecimiento por sus efectos neuroprotectores, antioxidantes y anabolizantes.
CL2007002502A1 (es) * 2006-08-31 2008-05-30 Hoffmann La Roche Variantes del factor de crecimiento similar a insulina-1 humano (igf-1) pegilados en lisina; metodo de produccion; proteina de fusion que la comprende; y su uso para tratar la enfermedad de alzheimer.

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE8703625D0 (sv) * 1987-09-18 1987-09-18 Kabivitrum Ab New medical use
US4876242A (en) * 1987-09-21 1989-10-24 Merck & Co., Inc. Human insulin-like growth factor analoges with reduced binding to serum carrier proteins and their production in yeast
US4988675A (en) * 1988-02-05 1991-01-29 Ciba-Geigy Corporation Method for preventing secondary effects
EP0327503B1 (en) * 1988-02-05 1993-03-10 Ciba-Geigy Ag Use of igf i in the manufacture of a medicament for the treatment of renal diseases
US5093317A (en) * 1989-06-05 1992-03-03 Cephalon, Inc. Treating disorders by application of insulin-like growth factor
GB8920381D0 (en) * 1989-09-08 1989-10-25 Greater Glasgow Health Board Treatment of insulin-resistant diabetes
US5126324A (en) * 1990-06-07 1992-06-30 Genentech, Inc. Method of enhancing growth in patients using combination therapy
US5374620A (en) * 1990-06-07 1994-12-20 Genentech, Inc. Growth-promoting composition and its use
SE9100099D0 (sv) * 1991-01-11 1991-01-11 Kabi Pharmacia Ab Use of growth factor
US5187151A (en) * 1991-02-12 1993-02-16 Genentech, Inc. Use of binding protein with igf-i as an anabolic growth promoting agent
US5202119A (en) * 1991-06-28 1993-04-13 Genentech, Inc. Method of stimulating immune response
AU2147192A (en) * 1991-06-28 1993-01-25 Genentech Inc. Method of stimulating immune response using growth hormone
SE9201573D0 (sv) * 1992-05-19 1992-05-19 Kabi Pharmacia Ab Use of igf-1
DE69327402T2 (de) * 1992-06-12 2000-05-04 Albert Einstein College Of Medicine Of Yeshiva University, Bronx Vorbeugung und behandlung der peripheren neuropathie
DK0661990T3 (da) * 1992-08-26 2002-06-17 Celtrix Pharma Fremgangsmåde til systemisk behandling af kataboliske tilstande og systemisk vævsbeskadigelse
US5273961A (en) * 1992-09-22 1993-12-28 Genentech, Inc. Method of prophylaxis of acute renal failure
CA2145501C (en) * 1992-10-29 2004-08-10 Ross G. Clark Method for treatment or prevention of obesity
CA2132871A1 (en) * 1993-01-25 1994-08-04 Alan C. Moses Method for modifying, diagnosing, and screening for igf-i sensitive cell barrier properties
DE69434403T2 (de) * 1993-09-20 2006-05-04 Celtrix Pharmaceuticals, Inc. Behandlung von immunologischen und hämatologischen Störungen mit IGFBP allein oder als Komplex mit IGF
DE69431527T2 (de) * 1993-11-15 2003-06-26 Celtrix Pharmaceuticals, Inc. Verwendung von igf-1 und igfbp-3 zur herstellung eines arzneimittels zur behandlung von einer nierenerkrankung
US5610134A (en) * 1994-04-15 1997-03-11 Genentech, Inc. Treatment of congestive heart failure
US5565428A (en) * 1995-05-22 1996-10-15 Genentech, Inc. Method of administration of IGF-I

Also Published As

Publication number Publication date
HK1009744A1 (en) 1999-06-11
EP0827408A1 (en) 1998-03-11
US5741776A (en) 1998-04-21
PT827408E (pt) 2007-01-31
JP2009132682A (ja) 2009-06-18
NZ307913A (en) 2005-07-29
ZA963995B (en) 1997-11-20
MX9708918A (es) 1998-06-30
AU5740696A (en) 1996-12-11
AU699113B2 (en) 1998-11-19
CA2218018A1 (en) 1996-11-28
DE69636654T2 (de) 2007-10-04
WO1996037216A1 (en) 1996-11-28
EP0827408B1 (en) 2006-10-25
ES2275276T3 (es) 2007-06-01
JPH11505265A (ja) 1999-05-18
DK0827408T3 (da) 2007-02-26
ATE343395T1 (de) 2006-11-15
DE69636654D1 (de) 2006-12-07

Similar Documents

Publication Publication Date Title
ZA963995B (en) Method of administration of IGF-I.
EP0592569A4 (en) COMPOSITION AND METHOD FOR TRANSDERMAL ADMINISTRATION OF DICLOFENAC.
UA42747C2 (uk) Похідні пептиду,фармацевтична композиція та спосіб стимулювання секреції гормону росту
AU1189792A (en) Biodegradable and bioabsorbable guide channels for use in nerve treatment and regeneration
ZA937148B (en) Dioic acids.
GR3037031T3 (en) Dermatological preparation and method for treating actinic keratoses
MY127622A (en) Method of treatment
GB9410639D0 (en) Method of improving fertilization
KR100226082B1 (en) Arylalkyl esters of 4,5-dihydroxy-9,10-dihydro-9,10-dioxo-2-anthracenecarboxylic acid having therapeutical activity
EA199700185A1 (ru) Способ уменьшения риска вертебральных переломов
GR3022935T3 (en) Product and use of it for the treatment of catabolic states comprising authentic igf-1 and hypocaloric amount of nutritients
ATE141789T1 (de) Zusammensetzung enthaltend dibucaine- hydrochlorid, ein salicylat, calciumbromid und ein antiphlogistisches steroid zur schmerzbekämpfung
PH30474A (en) Anit-atherosclerotic use of 17 alpha-dihydroequilin
IE842584L (en) Gaba-transaminase inhibitors
MX9705215A (es) Uso de 2-fenil-3-aroilbenzotiofenos para inhibir los efectos de la hormona del crecimiento.